BRCA2 and prostate carcinoma: Consonantly, a similar dependence on PARP-1 activity has been demonstrated clinically, where PARP-1 inhibition effectively limited tumor growth in BRCA2/1-mutated tumors (Fong et al, 2010), and showed single-agent efficacy in patients with advanced castration-resistant prostate cancer (a tumor type and stage known to express high levels of cyclin D1b) (Fong et al, 2010; Sandhu et al, 2010).